Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome
26 sept. 2024 12h34 HE
|
Minovia Therapeutics
MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria In pre-clinical studies, MNV-201 demonstrated improved...
Culture Biosciences Appoints Chris Williams as Chief Executive Officer
26 sept. 2024 12h05 HE
|
Culture Biosciences
South San Francisco, CA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Culture Biosciences, a leader in cloud-connect bioprocess development technologies, is pleased to announce the appointment of Chris...
BioNTX Announces 2024 Tech Transfer Showcase Finalists Pitch Competition at the 2024 iC³ Life Science & Healthcare Innovation Summit
26 sept. 2024 10h00 HE
|
BioNTX
ARLINGTON, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- BioNTX is pleased to announce the finalists for the 3rd Annual Tech Transfer Showcase, set for Friday, October 4th, at the 2024 iC³ Life Science...
EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy
26 sept. 2024 07h00 HE
|
EnnoDC
PRESS RELEASE EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy Versatile new technology featuring an...
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
26 sept. 2024 02h30 HE
|
Abivax
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy and...
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
26 sept. 2024 01h00 HE
|
Pharming Group N.V.
For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the...
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
25 sept. 2024 16h01 HE
|
Abivax
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease...
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
25 sept. 2024 08h30 HE
|
PRISM MarketView
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
24 sept. 2024 11h09 HE
|
Tevogen Bio Inc
WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Tersa Earth and Silica-X Sign MoU to Revolutionize Mining and Waste Management with AI-Powered Biotech and Zero-Waste Solutions
24 sept. 2024 09h00 HE
|
Tersa Earth Innovations Inc
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Fresh off its recognition as a Top Innovator in the World Economic Forum’s (WEF) Sustainable Mining Challenge, Tersa Earth Innovations Inc. announces...